{"filings":[{"id":97710,"accession_number":"0001193125-26-209899","cik":2100782,"company_name":"Generate Biomedicines, Inc.","ticker":"GENB","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Generate Q1 net loss widens to $61.7M, cash $516.6M post-IPO; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $61.7M vs $44.3M YoY; revenue $7.2M (down 18% from $8.8M).","Cash & equivalents $516.6M, includes $369.3M IPO proceeds; runway into H1 2028.","GB-0895 (anti-TSLP) Phase 3 SOLAIRIA-1/2 ongoing in severe asthma; Phase 1b in COPD.","GB-4362 (MMAE neutralizer) FDA Fast Track; first patient dosing expected mid-2026.","GB-5267 (MUC16 armored CAR T with Roswell Park) first patient expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":7224000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1693422792.8999999,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112820,"accession_number":"0001193125-26-085780","cik":2100782,"company_name":"Generate Biomedicines, Inc.","ticker":"GENB","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Generate Biomedicines adopts amended charter and bylaws for public company governance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended charter authorizes 500M common shares and 10M undesignated preferred shares.","Stockholder actions by written consent and ability to call special meetings eliminated.","Bylaws establish advance notice procedures for stockholder proposals and director nominations.","Changes previously disclosed in S-1 registration statement; effective upon IPO completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1693422792.8999999,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}